Comparing surgery and chemoradiotherapy for cervical esophageal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare the effectiveness of surgery versus definitive chemoradiotherapy in patients diagnosed with resectable cervical esophageal squamous cell carcinoma. Eligible participants will be those aged 18-75 who meet specific health criteria and have signed informed consent. The primary intervention involves esophagectomy, and the study will assess overall survival rates between the two treatment approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with resectable cervical esophageal squamous cell carcinoma (cT1b-T4aN0-3M0);
* Cervical esophageal cancers spreads upwards to involve the hypopharynx and downwards to involve the thoracic esophagus can also be included;
* Aged 18-75 years;
* Without any contraindication of operation;
* Hemoglobin \>=90 g/L; Leukocytes \>=4.0x10\^9/L; Absolute neutrophil count \>=1.5x10\^9/L; Platelet \>=100x10\^9/L;Total bilirubin \<=1.5 ULN; ALT \<=2.5 ULN; AST \<=2.5 ULN; Serum creatinine \<=1.5 ULN or creatinine clearance rate \>=50 mL/min (Cocheroft-Gault);INR \<=1.5 ULN; APTT \<=1.5 ULN;
* Without other malignancies;
* Expected R0 resection;
* ECOG PS 0-1;
* Volunteered to participate in the study, signed the informed consent form.

Exclusion Criteria:

* Without other malignancies;
* With mental diseases;
* With hemorrhagic disease;
* Inoperable patients;
* Pregnant or lactating women;
* Has a history of allergy to paclitaxel or cisplatin

Where it's running

• Cancer Hospital Chinese Academy of Medical Sciences
  Beijing, China Recruiting

Study contacts

• Principal investigator: Yin Li, MD — Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
• Study coordinator: Zhen Wang, MD
• Email: wangzhen@cicams.ac.cn
• Phone: +8613600892432

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cadonilimab and Lenvatinib in advanced kidney cancer

  This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Panjiayuan Nanli · NCT07909265

• Neoadjuvant therapy with nimotuzumab, toripalimab, nab-paclitaxel, and cisplatin for locally advanced head and neck cancer

  This study tests a pre-surgery treatment combining targeted therapy, immunotherapy, and chemotherapy to see if it helps patients with locally advanced, resectable head and neck squamous cell carcinoma.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Hebei, Hebei · NCT07906587

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

• Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread

  This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07893392

• Three-dimensional lattice radiotherapy with PD-1/PD-L1 inhibitors for advanced solid tumors

  This study tests whether adding lattice radiotherapy to PD-1/PD-L1 inhibitors is safe and helps people with advanced solid tumors that have grown or spread.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Shenzhen, Guangdong · NCT07865793

• Radiotherapy target-volume choices in locally advanced esophageal cancer during immunotherapy

  This observational study looks at how doctors outline the radiation area for locally advanced esophageal squamous cell cancer patients treated with radiotherapy and immunotherapy to see which approaches correlate with better outcomes.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07858630

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.